353 related articles for article (PubMed ID: 29104087)
21. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
22. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
[TBL] [Abstract][Full Text] [Related]
23. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
[TBL] [Abstract][Full Text] [Related]
25. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
28. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
29. [Germ cell tumors of the testes: state of the art].
Fléchon A; Droz JP
Cancer Radiother; 2000; 4(1):27-31. PubMed ID: 10742806
[TBL] [Abstract][Full Text] [Related]
30. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.
Christian JA; Huddart RA; Norman A; Mason M; Fossa S; Aass N; Nicholl EJ; Dearnaley DP; Horwich A
J Clin Oncol; 2003 Mar; 21(5):871-7. PubMed ID: 12610187
[TBL] [Abstract][Full Text] [Related]
31. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
32. One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis.
Mezvrishvili Z; Managadze L
Urol Int; 2005; 75(4):304-8. PubMed ID: 16327295
[TBL] [Abstract][Full Text] [Related]
33. Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.
Avulova S; Allen C; Morgans A; Moses KA
Urol Oncol; 2018 Jul; 36(7):342.e1-342.e6. PubMed ID: 29754945
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
[TBL] [Abstract][Full Text] [Related]
35. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
38. High-risk clinical stage I NSGCT: the case for RPLND.
Morash C; Cagiannos I
World J Urol; 2009 Aug; 27(4):449-53. PubMed ID: 19488758
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
Djaladat H; Nichols C; Daneshmand S
Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
[TBL] [Abstract][Full Text] [Related]
40. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
